Albertsons Opioid Ruling: Washington Judge Orders $900 Million After Nine-Week Bench Trial

In the Albertsons opioid ruling issued on Thursday, Nov. 5, 2026, King County Superior Court Judge Janet Helson ordered Albertsons Companies and its Safeway subsidiary to pay the State of Washington $900 million: $800 million to abate the opioid epidemic and $100 million in civil penalties under the Consumer Protection Act, plus the State's attorneys' fees and costs. The judgment, which Attorney General Nick Brown called the largest verdict believed to have been won in state history, is the first trial loss for the grocery chain on opioids and the clearest test yet of whether a state that opts out of a national deal can beat it in court.

The award is well short of the roughly $2.2 billion the State asked for at closing in September, and Albertsons has said it is weighing an appeal. But the structure of the ruling matters as much as the number. Judge Helson put the bulk of the money into a court-supervised abatement trust, imposed separate statutory penalties, and built in a fallback: if an appellate court throws out the abatement remedy, the penalty figure climbs to roughly $338 million. That design anticipates exactly the attack that sank the last big pharmacy abatement judgment in Ohio.

What did the judge decide in the Albertsons opioid ruling?

Judge Helson found Albertsons liable on both claims that survived to trial. She held that the company substantially contributed to a public nuisance under Washington law and that it violated the Washington Consumer Protection Act through its handling of controlled substances at its pharmacies. The decision followed a nine-week bench trial that opened on July 13, 2026, and closed in mid-September; no jury was involved, so the judge decided both liability and remedy.

According to the Attorney General's Office and contemporaneous reporting of the decision, the court found that Albertsons:

• failed to maintain adequate safeguards against the misuse and diversion of dangerous controlled substances, in violation of state and federal law;
• understaffed and undertrained its pharmacies relative to the controlled-substance volume they handled;
• failed to adequately investigate and document red flags on opioid prescriptions, and failed to identify and resolve suspicious orders;
• in some stores, did not allow pharmacists to turn away prescriptions written by known "pill mill" prescribers, including five prescribers whose licenses were later suspended or revoked, even after competing chains had blocked them; and
• did not use the dispensing data it had to identify high-risk prescribers and orders, or track its controlled-substance inventory closely enough to catch theft.

The ruling also carries injunctive terms. Reporting on the order describes a permanent requirement that Albertsons strengthen its controlled-substance dispensing procedures in Washington and certify its compliance to the Attorney General annually for five years.

How much does Albertsons have to pay Washington?

Albertsons must pay $900 million, plus the State's reasonable attorneys' fees and litigation costs, which have not yet been quantified. The headline number has three moving parts and one contingent part:

Component	Amount	Legal basis	Where the money goes
Abatement	$800 million	Public nuisance (equitable remedy)	Court-supervised trust for treatment, recovery and prevention
Civil penalties	$100 million	Washington Consumer Protection Act	State
Fees and costs	To be determined	Consumer Protection Act fee provision	State and its outside counsel
Alternative penalty (contingent)	About $338 million	Consumer Protection Act	Applies only if the abatement order is overturned on appeal
State's request at closing	About $2.2 billion	Share of a $44.4 billion abatement plan	Not awarded in full

Two comparisons frame the number. The $900 million is about 41% of what Washington asked for (the $800 million abatement alone is about 36%), and about $126 million more than the $774 million Albertsons agreed to pay to resolve substantially all state, local and tribal opioid claims everywhere else in the country under its April 14, 2026 framework. In other words, a single opt-out state has, at least at the trial level, won more than the national deal pays the rest of the nation combined.

The abatement figure is not compensatory damages and it is not Punitive Damages. It is the price of programs the court found necessary to remedy a public nuisance. That distinction drives the appellate fight and explains the contingent penalty.

Why is there a $338 million backup penalty?

The fallback exists because abatement is the most vulnerable part of any opioid nuisance judgment. If an appellate court holds that public nuisance cannot reach the dispensing of a lawful product, or that $800 million is damages dressed as equity, the abatement award falls. Judge Helson addressed that risk in advance: according to the ruling as reported by Reuters and the trade press, the civil penalty would rise to roughly $337.9 million, the amount she found Albertsons would otherwise owe under the Consumer Protection Act, if the abatement order does not survive.

The design converts an all-or-nothing appeal into a floor. Even a complete win on the nuisance theory leaves Albertsons facing more than three times the penalty it owes now. Defendants in other states should expect plaintiffs' counsel to ask for the same alternative structure.

Why did Washington reject the $774 million national settlement?

Washington declined the national framework because it has done better by trying its own cases. In 2021 the State walked away from the national distributor settlement, under which it stood to receive up to $417.9 million, and settled at the close of a trial in 2022 for up to $518 million from McKesson, Cardinal Health and AmerisourceBergen. Brown described the Albertsons result as vindication of the same strategy: "We thought the liability and the accountability that we needed to achieve against Albertsons was greater than the efforts that we were seeing elsewhere," he said, adding that a $900 million verdict "that we proved before a judge" confirmed the approach.

The Albertsons framework announced on April 14, 2026, is payable over nine years, is conditioned on participation thresholds, and expressly is not an admission of liability. Albertsons recorded a fourth-quarter loss of about $480.8 million driven by the settlement charge. The Washington judgment is separate from that framework and is not reduced by it.

Washington opioid recovery	Amount	Route
McKesson, Cardinal Health, AmerisourceBergen (2022)	Up to $518 million	Opt-out; settled at the close of trial
Kroger (2024)	$47.5 million	Settled the companion King County case
Albertsons national framework (2026)	$774 million nationwide	Declined by Washington
Albertsons judgment (Nov. 5, 2026)	$900 million plus fees and costs	Bench trial; appeal possible

How did the case get to a $900 million judgment?

The case was filed in December 2022, when then-Attorney General Bob Ferguson sued Albertsons, Kroger and Rite Aid in King County Superior Court. Kroger settled for $47.5 million in 2024. Albertsons went to trial alone.

Date	Event
December 2022	Washington sues Albertsons, Kroger and Rite Aid in King County Superior Court
2024	Kroger settles for $47.5 million
April 14, 2026	Albertsons announces a $774 million national framework; Washington stays out
June 1, 2026	Judge Helson rules Albertsons and Safeway had a legal duty to prevent diversion
July 13, 2026	Bench trial opens
July 30, 2026	Court strikes Albertsons' statute-of-limitations defense, keeping 14 years of claims in the case
Aug. 27, 2026	Court denies Albertsons' midtrial motion for judgment as a matter of law
Mid-September 2026	Closing arguments; the State asks for about $2.2 billion
Nov. 5, 2026	Ruling for the State: $900 million plus fees and costs

Three pretrial and midtrial rulings did most of the work. The June 1 duty ruling established that a dispenser of controlled substances owes a duty to prevent diversion, which turned every unresolved red flag into a potential breach. The July 30 ruling on the Statute of Limitations kept the full 2006-2022 period in play, which is why the State could present 641 million pills and more than 6.5 million red-flag fills rather than a few years' worth. And the Aug. 27 denial of judgment as a matter of law signaled, in a case where the same judge would weigh the evidence, that the State's proof was sufficient to win.

The State was represented by the Attorney General's Office with Baron & Budd as lead special counsel, whose lawyers were designated Special Assistant Attorneys General, and co-counsel Levin Papantonio, Powell & Majestro, and Farrell & Fuller. Those firms worked on the Contingency Fee and outside-counsel terms typical of state opioid mandates, which is why the fee-and-cost award, still to be set, matters to the plaintiffs' bar.

Will Albertsons appeal the $900 million opioid verdict?

Albertsons has not yet filed an appeal but has signaled one. Its statement: "Albertsons Companies is disappointed by the court's ruling and respectfully disagrees with its conclusions. We are reviewing the decision closely and will evaluate all available options, including appeal." The company denies wrongdoing.

The likely sequence in Washington practice is post-trial motions in the superior court, entry of a final judgment if one has not already been entered, and a notice of appeal to Division I of the Washington Court of Appeals, which hears King County cases. Either side could ask the Washington Supreme Court to take the case directly given its statewide public importance. To stop collection while it appeals, Albertsons would need to supersede the judgment, ordinarily by posting a bond or other security. None of that will move quickly; as Washington press coverage put it, the money will take a while to reach the State.

On review, the standards split. Findings of fact from a bench trial, such as how many red-flag prescriptions were filled and what Albertsons' policies required, get deferential substantial-evidence review. Conclusions of law, including whether Washington's nuisance statutes reach this conduct and whether an $800 million abatement trust is a proper equitable remedy, get de novo review. That is the gap the $338 million fallback was built to fill.

Does the Ohio Supreme Court's opioid ruling threaten the Albertsons judgment?

It is Albertsons' best argument, but the fit is imperfect. On Dec. 10, 2024, the Supreme Court of Ohio answered a certified question in the federal opioid Multidistrict Litigation (MDL) by holding that the Ohio Product Liability Act abrogated common-law public nuisance claims arising from product sales. That answer gutted the roughly $650.9 million abatement judgment Lake and Trumbull Counties had won against CVS, Walgreens and Walmart after a 2021 jury trial.

Washington's case differs on the points that decided Ohio. Washington pleaded its statutory nuisance provisions rather than a judge-made tort. The plaintiff is the State enforcing the Consumer Protection Act as sovereign, not a county seeking its own budget costs. And the theory is about conduct, such as filling red-flag prescriptions and failing to report suspicious orders, rather than the claim that selling a lawful product is itself a nuisance. Albertsons can still argue that Washington's product liability statute should be read the same way, or that apportioning a statewide plan to one dispenser is damages in disguise. The contingent penalty means even a win on that point would not wipe out the judgment.

Who gets the $800 million opioid abatement money?

The $800 million goes to a court-supervised trust rather than the State's general fund. According to the Attorney General's Office, the money is earmarked for addiction treatment, recovery resources and prevention across Washington. Brown framed it this way: "This verdict can't undo the devastating harms of the opioid crisis, but it will provide desperately needed resources to support treatment and prevent future crises." More than 26,000 Washingtonians have died of opioid overdoses since 1999, according to the State.

Coverage of the ruling does not yet describe how the trust will be governed, whether local governments get a direct share, or how quickly money would be paid out. Those terms, along with the fee award, are the details to watch in the written judgment and any post-trial orders. No money moves while an appeal is pending and the judgment is superseded.

What it means for state AGs, plaintiffs' firms and pharmacy defendants

For state attorneys general. Washington now has three results to point to: a $518 million opt-out distributor recovery, a $47.5 million Kroger settlement, and a $900 million trial judgment against a defendant whose national deal was $774 million. Offices deciding whether to join the next national framework have a concrete measure of what opting out can be worth, and of what it costs: years of litigation and a nine-week trial with no guaranteed outcome.

For plaintiffs' firms on AG mandates. The economics improved, with caveats. A judgment that includes fees and costs and builds in an appeal-proof penalty floor is easier to fund than an all-or-nothing abatement award. But the firms still carry the appellate timeline, and abatement remedies have a mixed record on review. The alternative-penalty structure is the transferable lesson.

For pharmacy and retail defendants. A national settlement does not buy peace where a state opts out, and the holdout state will be the one most confident in its evidence. The findings here centered on documentation: unresolved red flags, blocked-prescriber lists not honored, inventory controls, staffing. Those records are created years before any lawsuit.

For Mass Tort practitioners generally. Opioid litigation is now mostly settlement administration, but the Washington judgment keeps public-nuisance abatement alive as a trial remedy in at least one state. Expect it to be cited in other public-nuisance cases brought by governments, from PFAS to social media, and expect defendants to cite Ohio in response.

Frequently asked questions

What did the judge decide in the Albertsons opioid ruling?

Judge Janet Helson of King County Superior Court found on Nov. 5, 2026, that Albertsons and Safeway substantially contributed to a public nuisance and violated Washington's Consumer Protection Act, and ordered them to pay $900 million plus fees and costs.

How much does Albertsons have to pay Washington?

$900 million: $800 million in abatement paid into a court-supervised trust and $100 million in civil penalties, plus the State's reasonable attorneys' fees and litigation costs. If the abatement is overturned, the penalty rises to about $338 million.

Will Albertsons appeal the $900 million opioid verdict?

Albertsons has not filed an appeal yet but said it "respectfully disagrees" with the ruling and will evaluate all options, including appeal; an appeal would go to the Washington Court of Appeals unless the state Supreme Court takes it directly.

Why did Washington reject the $774 million national settlement?

Washington has consistently opted out of national opioid deals to try its own cases, a strategy that produced up to $518 million from the three distributors in 2022 against up to $417.9 million under the national deal.

How many opioid pills did Albertsons dispense in Washington?

The State alleged Albertsons dispensed more than 641 million opioid pills in Washington from 2006 to 2022, and the court found that more than 6.5 million opioid prescriptions filled in that period triggered at least one commonly accepted red flag.

Does the ruling affect Albertsons' national opioid settlement?

No. The Washington judgment is separate from the $774 million national framework announced April 14, 2026, which covers other state, local and tribal claims and does not include Washington.